ArticleRegenerative therapy2026
Human induced pluripotent stem cell-derived cardiomyocyte patch enhances cardiac regeneration in a J2N-k hamster model of dilated cardiomyopathy.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dilated cardiomyopathy (DCM) is a major cause of heart failure with limited therapeutic options beyond heart transplantation. This study aimed to evaluated the therapeutic potential of human induced pluripotent stem cell-derived cardiomyocyte (hiPS-CM) patch transplantation in a genetic DCM model. Methods: hiPS-CM patches were transplanted onto the left ventricular surface of adult J2N-k hamsters with DCM. Cardiac function, survival, and histological evaluation were assessed. Single-nucleus RNA sequencing using left ventricular myocardium was performed to investigate cell-type-specific transcriptional alteration associated with treatment. Results: hiPS-CM patch transplantation preserved cardiac function [left ventricular ejection fraction, 41.2 (38.9 - 42.8) vs. 43.4 (40.5 - 44.6) %, P = 0.07], improved survival [Hazrod ratio 0.39 (95% confidence interval 0.16 - 0.63), P < 0.05], reduced myocardial fibrosis [fibrous area, 10.2 (9.4 - 12.1) vs. 14.1 (13.1 - 18.3) %, P < 0.05], and increased capillary density [CD-31 positive cells cout, 373.2 (336.4 - 441.3) vs. 210.7 (157.4 - 232.3) cells/mm Conclusions: hiPS-CM patch transplantation exerts therapeutic effects through multicellular mechanisms, including enhanced angiogenesis, improved myocardial microenvironment, and modulation of fibrosis. These findings support the feasibility of hiPS-CM patch therapy as a regenerative strategy for end-stage DCM and provide mechanistic insights into its therapeutic action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.